Key takeaways
- A new large-scale observational study links GLP-1 drugs to a 14% reduction in asthma and COPD attacks.
- Semaglutide (Ozempic/Wegovy) performed the best, showing a 30% reduction in overall respiratory exacerbations.
- The respiratory benefits were independent of weight loss or metabolic changes, suggesting direct pulmonary mechanisms.
- Clinical experts emphasize that randomized trials are still needed before GLP-1s can be prescribed directly for lung conditions.
What happened
A major real-world study presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain, reveals that GLP-1 receptor agonists are associated with a 14% lower risk of asthma and COPD flare-ups. The research, led by Dr. Chloe Bloom of Imperial College London, analyzed electronic health records from the United Kingdom to evaluate respiratory outcomes in patients using GLP-1 drugs for comorbid conditions like type 2 diabetes.
Why it matters
This study expands the clinical utility of GLP-1 medications far beyond weight loss and glycemic control, offering potential direct pulmonary benefits for patients with chronic airway diseases. For cash-paying consumers navigating online telehealth providers, these findings add substantial weight to the overall value proposition of these medications. When insurance coverage is denied, understanding that a drug like semaglutide may also lower the risk of expensive emergency room visits or hospitalizations for respiratory issues helps justify the out-of-pocket expense.
What the data says
Using weighted propensity scoring, researchers analyzed a cohort of over 1.1 million UK adults with asthma or COPD, comparing 8,266 new users of GLP-1 drugs with 20,273 new users of sulfonylureas. An exacerbation was defined as a short course of oral steroids, an emergency department visit, hospitalization, or death.
The study revealed distinct differences between individual GLP-1 medications:
- Overall GLP-1 Class: Associated with a 14% overall reduction in respiratory exacerbations.
- Semaglutide (Ozempic/Wegovy): Tied to a significant 30% reduction in overall respiratory exacerbations. This broke down further to a 38% reduction in asthma attacks and a 21% reduction in COPD flare-ups.
- Exenatide (Byetta/Bydureon): Tied to a 23% reduction in exacerbations.
- Dulaglutide (Trulicity): Associated with a 12% reduction.
- Liraglutide (Victoza/Saxenda) and Lixisenatide (Adlyxin): Showed no change in exacerbation rates.
Remarkably, semaglutide's pulmonary benefits were not modified by baseline body mass index (BMI), HbA1c, insulin resistance, or weight changes during treatment. According to Dr. Bloom, the fact that metabolic factors did not influence the results supports the possibility of direct pulmonary mechanisms rather than benefits derived purely from weight loss.
How it compares
For US consumers evaluating GLP-1 options, these findings highlight crucial differences between individual active ingredients. While tirzepatide (Mounjaro/Zepbound) remains a highly popular choice for weight loss, this respiratory dataset specifically highlights semaglutide as the top performer for lung health, closely followed by older medications like exenatide.
When buying these medications online, price and clinical utility must be balanced:
- Brand-name options: Brand-name Wegovy and Ozempic carry list prices of approximately $1,349 and $935 per month, respectively.
- Compounded alternatives: For cash-paying buyers without insurance coverage, compounded semaglutide through online telehealth providers typically ranges from $199 to $399 per month.
While the study examined brand-name formulations, the active pharmaceutical ingredient (API) in compounded semaglutide is chemically identical to that of Ozempic and Wegovy. Consequently, cash-paying buyers who choose compounded options due to high brand-name costs may still experience these same pulmonary benefits, making the compounded vs brand name semaglutide comparison even more relevant for those with respiratory comorbidities.
How this fits the bigger picture
This research fits into a rapidly growing body of clinical evidence showing that GLP-1 drugs function as systemic multi-system therapies rather than simple "diet pills." We have recently seen how these medications are expanding into other therapeutic areas. For example, as explored in our coverage of how GLP-1s cut tuberculosis and infection risks, these therapies appear to modulate systemic inflammatory and immune responses.
Furthermore, as the FDA continues to expand official approvals—such as its landmark decision covered in our report on how the FDA approves Mounjaro for cardiovascular risk reduction—the clinical justification for these high-cost therapies grows. This is especially vital for consumers facing insurance barriers. As discussed in our guide on what insurance covers GLP-1, insurers frequently deny coverage for weight loss alone. Demonstrating secondary benefits like reduced respiratory exacerbations could eventually help patients build stronger cases for coverage or feel more confident paying cash through telehealth platforms.
What happens next
While the real-world data is highly encouraging, experts emphasize that this observational study does not prove direct causation. Researchers like Dr. Alexander Mathioudakis of the University of Manchester and Dr. Marie Spreckley of the University of Cambridge have cautioned that patients should not seek semaglutide specifically for asthma or change their existing respiratory regimens based on these findings.
The next crucial step is the initiation of randomized clinical trials that directly measure respiratory outcomes, including lung function, symptoms, and quality of life. Until these clinical trials are completed and official FDA indications are updated, online telehealth providers will continue prescribing these medications primarily for weight loss and type 2 diabetes, while patients with comorbid asthma or COPD may simply enjoy these pulmonary benefits as a welcome secondary effect.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare provider before starting or changing any medication regimen.